Active Aβ vaccination fails to enhance amyloid clearance in a mouse model of Alzheimer's disease with Aβ42-driven pathology

Journal of Neuroimmunology

Volumn 247, Issue 1-2, 2012, Pages 95-99

  Nemirovsky, Anna ^a   Shapiro, Jenny ^a   Baron, Rona ^a   Kompaniets, Alex ^a   Monsonego, Alon ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

A antibodies; Alzheimer's disease; Amyloid beta peptide; Vaccine

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE MUTATION; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MICROGLIA; MOUSE; NONHUMAN; PRESENELINE 1 GENE; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FREUND'S ADJUVANT; HUMANS; IMMUNOTHERAPY, ACTIVE; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MUTATION; PEPTIDE FRAGMENTS; PRESENILIN-1; T-LYMPHOCYTES;

EID: 84860833668     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.03.017     Document Type: Article

References (22)

1. Boche D., Denham N., Holmes C., Nicoll J.A. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol. 2010, 120:369-384.
2. Butovsky O., Koronyo-Hamaoui M., Kunis G., Ophir E., Landa G., Cohen H., Schwartz M. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11784-11789.
3. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., St George Hyslop P., Selkoe D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 1997, 3:67-72.
4. Ellmerich S., Takacs K., Mycko M., Waldner H., Wahid F., Boyton R.J., Smith P.A., Amor S., Baker D., Hafler D.A., Kuchroo V.K., Altmann D.M. Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis. Eur. J. Immunol. 2004, 34:1839-1848.
5. Fisher Y., Nemirovsky A., Baron R., Monsonego A. T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease. PLoS One 2010, 5:e10830.
6. Frenkel D., Maron R., Burt D.S., Weiner H.L. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest. 2005, 115:2423-2433.
7. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., Lieberburg I., Schenk D., Seubert P., McConlogue L. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:1550-1555.
8. Lemere C.A., Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nat. Rev. Neurol. 2010, 6:108-119.
9. Lord A., Gumucio A., Englund H., Sehlin D., Sundquist V.S., Soderberg L., Moller C., Gellerfors P., Lannfelt L., Pettersson F.E., Nilsson L.N. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2009, 36:425-434.
10. Mehta P.D., Pirttila T., Mehta S.P., Sersen E.A., Aisen P.S., Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 2000, 57:100-105.
11. Moehlmann T., Winkler E., Xia X., Edbauer D., Murrell J., Capell A., Kaether C., Zheng H., Ghetti B., Haass C., Steiner H. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8025-8030.
12. Monsonego A., Imitola J., Petrovic S., Zota V., Nemirovsky A., Baron R., Fisher Y., Owens T., Weiner H.L. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5048-5053.
13. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
14. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006, 26:10129-10140.
15. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Holscher C., Mathews P.M., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006, 7:940-946.
16. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
17. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
18. Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J. Exp. Med. 2010, 220:95-106.
19. Wang A., Das P., Switzer R.C., Golde T.E., Jankowsky J.L. Robust amyloid clearance in a mouse model of Alzheimer's Disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J. Neurosci. 2011, 31:4124-4136.
20. Wirths O., Erck C., Martens H., Harmeier A., Geumann C., Jawhar S., Kumar S., Multhaup G., Walter J., Ingelsson M., Degerman-Gunnarsson M., Kalimo H., Huitinga I., Lannfelt L., Bayer T.A. Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J. Biol. Chem. 2010, 285:41517-41524.
21. Zhang Y.W., Thompson R., Zhang H., Xu H. APP processing in Alzheimer's disease. Mol. Brain 2011, 4:3.
22. Zota V., Nemirovsky A., Baron R., Fisher Y., Selkoe D.J., Altmann D.M., Weiner H.L., Monsonego A. HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele. J. Immunol. 2009, 183:3522-3530.